BIIB

BIIB

USD

Biogen Inc. Common Stock

$124.990-4.560 (-3.520%)

Prix en Temps Réel

Healthcare
Drug Manufacturers - General
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$129.550

Haut

$129.580

Bas

$124.680

Volume

1.14M

Fondamentaux de l'Entreprise

Capitalisation Boursière

18.3B

Industrie

Drug Manufacturers - General

Pays

United States

Statistiques de Trading

Volume Moyen

1.48M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $110.04Actuel $124.990Haut $236.48

Actualités Connexes

GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved

Voir plus
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
GlobeNewswire

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA®

Voir plus
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Analyst Upgrades

RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target

RBC Capital analyst Brian Abrahams reiterates Biogen with a Outperform and maintains $213 price target.

Voir plus
RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Biogen with a Buy and maintains $187 price target.

Voir plus
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target
GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA

Voir plus
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Analyst Upgrades

Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target

Piper Sandler analyst David Amsellem reiterates Biogen with a Neutral and maintains $115 price target.

Analyst Upgrades

Wedbush Reiterates Neutral on Biogen, Maintains $121 Price Target

Wedbush analyst Laura Chico reiterates Biogen with a Neutral and maintains $121 price target.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.